Chemotherapy-Induced Myelosuppression Treatment Market Report 2026

The chemotherapy-induced myelosuppression treatment market size has grown steadily in recent years. It will grow from $8.35 billion in 2025 to $8.73 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to increasing intensity of chemotherapy regimens, rising incidence of treatment-related cytopenias, expansion of hospital-based oncology care, availability of supportive hematology treatments, improved diagnostic capabilities.

The chemotherapy-induced myelosuppression treatment market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2030 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to increasing focus on long-acting hematopoietic agents, rising adoption of personalized dosing strategies, expansion of outpatient supportive care services, growing investment in biologic drug development, advancements in bone marrow support therapies. Major trends in the forecast period include increasing adoption of growth factor therapies, rising use of prophylactic treatment strategies, growing emphasis on infection prevention protocols, expansion of personalized myelosuppression management, enhanced monitoring of blood cell counts.

The increasing prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced myelosuppression treatment market in the coming years. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which can invade nearby tissues and organs, disrupt normal bodily functions, and pose serious risks to overall health. The rising incidence of cancer is attributed to factors such as exposure to pollution, radiation, certain chemicals, and carcinogenic substances. Chemotherapy-induced myelosuppression treatment plays a critical role in cancer care by managing the blood-related side effects caused by chemotherapy, which remains a primary treatment approach for many cancers. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 individuals were newly diagnosed with cancer in Australia in 2023, equating to more than 450 new cases per day, with males accounting for around 55% of these diagnoses. Therefore, the growing burden of cancer is fueling the expansion of the chemotherapy-induced myelosuppression treatment market.

Major companies operating in the chemotherapy-induced myelosuppression treatment market are concentrating on the development of innovative therapies, such as long-acting granulocyte colony-stimulating factor (G-CSF) products, to improve patient convenience, enhance treatment adherence, reduce injection frequency, and optimize overall clinical outcomes for patients undergoing chemotherapy. Long-acting G-CSF therapies are biologic agents designed to stimulate the bone marrow to produce neutrophils over an extended duration. For instance, in May 2025, Mabwell, a China-based biopharmaceutical company, received approval from the National Medical Products Administration (NMPA) for Albipagrastim Alfa for Injection (Mailisheng), a recombinant human G-CSF fused with albumin to extend its half-life and support improved neutrophil recovery. The formulation incorporates recombinant human serum albumin (HSA), delivering a prolonged therapeutic effect that enables less frequent dosing while maintaining effective neutrophil stimulation, representing a significant advancement over conventional G-CSF therapies that require daily administration.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer seeks to strengthen its oncology and biopharmaceutical portfolio by leveraging Seagen’s expertise in antibody-drug conjugates and targeted cancer treatments, thereby enhancing its position in the oncology market and advancing therapeutic options for patients. Seagen Inc. is a US-based company specializing in the development of innovative monoclonal antibody-based therapies, including treatments addressing chemotherapy-induced myelosuppression.

Major companies operating in the chemotherapy-induced myelosuppression treatment market are Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Novartis AG, Glaxo Smith Kline plc, Amgen Inc., Viatris Inc., Biogen SA, Bausch Health Companies Inc., Cipla Inc., Hikma Pharmaceuticals PLC,Lupin Ltd, Seagen Inc, Mission Pharmacal Company, G1 Therapeutics Inc., Spectrum Pharmaceuticals Inc., Partner Therapeutics Inc., Myelo Therapeutics GmbH, Evive Biotech Inc.

North America was the largest region in the chemotherapy-induced myelosuppression treatment market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced myelosuppression treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced myelosuppression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chemotherapy-induced myelosuppression treatment market by increasing costs of imported biologics, injectable delivery systems, diagnostic reagents, and cold-chain logistics equipment. Healthcare systems in North America and Europe are most affected due to reliance on imported growth factors and specialty drugs, while Asia-Pacific experiences higher manufacturing and export costs. These tariffs are contributing to higher therapy prices and constrained hospital budgets. However, they are also supporting domestic biologics manufacturing, regional production of injectables, and investments in local pharmaceutical supply chains that enhance long-term treatment accessibility.

The chemotherapy-induced myelosuppression treatment market research report is one of a series of new reports that provides chemotherapy-induced myelosuppression treatment market statistics, including chemotherapy-induced myelosuppression treatment industry global market size, regional shares, competitors with a chemotherapy-induced myelosuppression treatment market share, detailed chemotherapy-induced myelosuppression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced myelosuppression treatment industry. This chemotherapy-induced myelosuppression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy-induced myelosuppression treatment refers to therapeutic approaches used to manage and reduce the suppression of bone marrow activity caused by chemotherapy drugs. The primary objective of these treatments is to control symptoms, prevent complications such as infections or bleeding disorders, and support patients in safely continuing their chemotherapy regimens.

The main indication types of chemotherapy-induced myelosuppression treatment include anemia, neutropenia, and thrombocytopenia. Anemia in this context refers to a condition in which the body does not have sufficient healthy red blood cells, leading to symptoms such as fatigue, weakness, and shortness of breath. The drug classes used include growth factors, erythropoietin-stimulating agents, thrombopoietic agents, iron supplements, and other related drug classes. These treatments are available through routes of administration such as oral and injectable forms and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

The chemotherapy-induced myelosuppression treatment market includes revenues earned by entities by providing services such as red blood cell transfusions, platelet transfusions, antibiotic therapy, and supportive care and related erythropoiesis-stimulating agents, antibiotics, colony-stimulating factors (CSFs), diagnostic kits and hydration solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.